Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Esther Wei Yin Chang, Valerie Shiwen Yang, Shin Yeu Ong, Hilda Xueqi Kang, Boon Yee Lim, Sanjay de Mel, Esther Ka Yan Ng, Michelle Limei Poon, Ya Hwee Tan, Jianbang Chiang, Eileen Poon, Nagavalli Somasundaram, Mohamad Farid, Tiffany Tang, Miriam Tao, Lay Poh Khoo, Chee Leong Cheng, Dachuan Huang, Choon Kiat Ong, Soon Thye Lim & Jason Yongsheng Chan. (2023) Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study. Leukemia & Lymphoma 64:11, pages 1782-1791.
Read now
Read now
Eric Tse, Rex Au-Yeung & Yok-Lam Kwong. (2019) Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas. Expert Review of Hematology 12:11, pages 927-935.
Read now
Read now
Articles from other publishers (51)
Le Yin, Qingyang Zhang, Sisi Xie, Zhao Cheng, Ruijuan Li, Hongkai Zhu, Qian Yu, Huan Yuan, Canfei Wang, Hongling Peng & Guangsen Zhang. (2023) HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt–autophagy pathway. Human Cell 36:4, pages 1564-1577.
Crossref
Crossref
Kapil Kumar, Ranjana Das, Barsha Thapa, Bharti Rakhecha, Sapna Srivastava, Kumari Savita, Monazza Israr, Debabrata Chanda, Dibyendu Banerjee, Karuna Shanker, DU Bawankule, Benedetta Santini, Maria Luisa Di Paolo, Lisa Dalla Via, Daniele Passarella & Arvind Singh Negi. (2023) Dual targeted 2-Benzylideneindanone pendant hydroxamic acid group exhibits selective HDAC6 inhibition along with tubulin stabilization effect. Bioorganic & Medicinal Chemistry 86, pages 117300.
Crossref
Crossref
Nan Sun, Kexin Yang, Wenzhong Yan, Mingyue Yao, Chengcheng Yu, Wenwen Duan, Xiaoke Gu, Dong Guo, Hualiang Jiang, Chengying Xie & Jianjun Cheng. (2023) Design and Synthesis of Triazole-Containing HDAC Inhibitors That Induce Antitumor Effects and Immune Response. Journal of Medicinal Chemistry 66:7, pages 4802-4826.
Crossref
Crossref
Mingyang Deng, Han Xiao, Hongling Peng, Huan Yuan, Xiang Xiao & Sufang Liu. (2022) Chidamide works synergistically with Dasatinib by inducing cell-cycle arrest and apoptosis in acute myeloid leukemia cells. Molecular and Cellular Biochemistry 478:4, pages 851-860.
Crossref
Crossref
Christophe Blanquart. 2023. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
507
538
.
Jasmine M. Cross, Megan E. Coulson, Joshua P. Smalley, Wiktoria A. Pytel, Ozair Ismail, Justin S. Trory, Shaun M. Cowley & James T. Hodgkinson. (2022) A ‘click’ chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras. RSC Medicinal Chemistry 13:12, pages 1634-1639.
Crossref
Crossref
Eric Tse, Wei-Li Zhao, Jie Xiong & Yok-Lam Kwong. (2022) How we treat NK/T-cell lymphomas. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Cancan Luo, Tiantian Yu, Ken H. Young & Li Yu. (2022) HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression组蛋白去乙酰化酶(HDAC)抑制剂西达本胺联合维奈托克通过下调MYC、BCL2和TP53的表达协同抑制弥漫性大B细胞淋巴瘤的生长. Journal of Zhejiang University-SCIENCE B 23:8, pages 666-681.
Crossref
Crossref
Cristina Maccallini, Alessandra Ammazzalorso, Barbara De Filippis, Marialuigia Fantacuzzi, Letizia Giampietro & Rosa Amoroso. (2022) HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer. Pharmaceuticals 15:6, pages 667.
Crossref
Crossref
Wenfang Bao, Zhe Zhu, Yong Gao & Jingde Chen. (2022) Transcriptome Profiling Analysis Identifies LCP1 as a Contributor for Chidamide Resistance in Gastric Cancer. Pharmaceutical Research 39:5, pages 867-876.
Crossref
Crossref
Yu-bo Zhou, Yang-ming Zhang, Hong-hui Huang, Li-jing Shen, Xiao-feng Han, Xiao-bei Hu, Song-da Yu, An-hui Gao, Li Sheng, Ming-bo Su, Xiao-li Wei, Yue Zhang, Yi-fan Zhang, Zhi-wei Gao, Xiao-yan Chen, Fa-jun Nan, Jia Li & Jian Hou. (2021) Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma. Acta Pharmacologica Sinica 43:4, pages 1091-1099.
Crossref
Crossref
Shao-Chuan Wang, Chia-Ying Yu, Yao-Cheng Wu, Ya-Chuan Chang, Sung-Lang Chen & Wen-Wei Sung. (2022) Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model. Cancer Letters 530, pages 8-15.
Crossref
Crossref
Eric Tse & Yok-Lam Kwong. (2022) Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies. Cancers 14:3, pages 597.
Crossref
Crossref
Bocheng Wu, Quaovi H. Sodji & Adegboyega K. Oyelere. (2022) Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges. Cancers 14:3, pages 552.
Crossref
Crossref
Jia-Shiong Chen, Cheng-Han Chou, Yi-Hong Wu, Mu-Hsuan Yang, Sz-Hao Chu, Ye-Su Chao & Chia-Nan Chen. (2022) CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor. Scientific Reports 12:1.
Crossref
Crossref
Xingrui He, Zi Hui, Li Xu, Renren Bai, Yuan Gao, Zongcheng Wang, Tian Xie & Xiang-Yang Ye. (2022) Medicinal chemistry updates of novel HDACs inhibitors (2020 to present). European Journal of Medicinal Chemistry 227, pages 113946.
Crossref
Crossref
Richard A. Stein & Abhi N. Deverakonda. 2023. Cancer Research: An Interdisciplinary Approach. Cancer Research: An Interdisciplinary Approach
183
240
.
Xiang Qiu, Lv Zhu, Huan Wang, Yan Tan, Zhuang Yang, Linyu Yang & Li Wan. (2021) From natural products to HDAC inhibitors: An overview of drug discovery and design strategy. Bioorganic & Medicinal Chemistry 52, pages 116510.
Crossref
Crossref
Zixue Zhang, Qingwei Zhang, Hao Zhang, Minru Jiao, Zheng Guo, Xinyan Peng, Lei Fu & Jianqi Li. (2021) Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities. Bioorganic Chemistry 117, pages 105407.
Crossref
Crossref
Mengya Zhong, Fusheng Lin, Yuelong Jiang, Guangchao Pan, Jinshui Tan, Hui Zhou, Qian Lai, Qinwei Chen, Manman Deng, Jie Zha & Bing Xu. (2021) Therapeutic Interaction of Apatinib and Chidamide in T-Cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis. Journal of Personalized Medicine 11:10, pages 977.
Crossref
Crossref
Jocelyn F. ChenQin Yan. (2021) The roles of epigenetics in cancer progression and metastasis. Biochemical Journal 478:17, pages 3373-3393.
Crossref
Crossref
Yang Xi, Dai Jingying, Li Chenglong, Zheng Hong, Zhang Rong, Wang Xiaodong, Wang Chunsen & Huang Xiaobing. (2021) Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Jianping Kong & Andrew L. Feldman. 2021. The Peripheral T‐Cell Lymphomas. The Peripheral T‐Cell Lymphomas
129
144
.
Arshdeep Singh, Ting-Yu Chang, Navdeep Kaur, Kai-Cheng Hsu, Yun Yen, Tony Eight Lin, Mei-Jung Lai, Sung-Bau Lee & Jing-Ping Liou. (2021) CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. European Journal of Medicinal Chemistry 215, pages 113169.
Crossref
Crossref
Lixia Cao, Shaorong Zhao, Qianxi Yang, Zhendong Shi, Jingjing Liu, Teng Pan, Dongdong Zhou & Jin Zhang. (2021) Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Shabir Ahmad Ganai, Farooq Ahmad Sheikh & Zahoor Ahmad Baba. (2020) Plant flavone Chrysin as an emerging histone deacetylase inhibitor for prosperous epigenetic‐based anticancer therapy. Phytotherapy Research 35:2, pages 823-834.
Crossref
Crossref
Liangliang Li, Chongyang Wu, Ye Chai, Chi Dong & Li Zhao. (2021) Chidamide induces long-term remission in rare subcutaneous panniculitis-like T-cell lymphoma: An unusual case report and literature review. International Journal of Immunopathology and Pharmacology 35, pages 205873842110093.
Crossref
Crossref
Lulu Liu, Jingjing Zhang, Xianning Zhang, Panpan Cheng, Lei Liu, Qian Huang, Haihui Liu, Saisai Ren, Peng Wei, Cuiling Wang, Cuiyun Dou, Lulu Chen, Xin Liu, Hao Zhang & Mingtai Chen. (2020) HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target. Journal of Molecular Medicine 99:1, pages 107-118.
Crossref
Crossref
Ping Zhang & Mingzhi Zhang. (2020) Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. Clinical Epigenetics 12:1.
Crossref
Crossref
Yuxiang Luo & Huilin Li. (2020) Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). International Journal of Molecular Sciences 21:22, pages 8828.
Crossref
Crossref
Yue Xie, Ping Tang, Xinyue Xing, Yao Zhao, Shengqi Cao, Shengde Liu, Xiaoxu Lu & Liyun Zhong. (2020) In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 241, pages 118669.
Crossref
Crossref
Na Zhang, Pan Sun, Haizhen Jin, Yuqin Yang, Qingya Zhao, Lin Zhou, Lili Guo, Xiaohua Yang & Liming Lu. (2020) Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer. Anti-Cancer Drugs 31:7, pages 702-708.
Crossref
Crossref
Jian Cao & Qin Yan. (2020) Cancer Epigenetics, Tumor Immunity, and Immunotherapy. Trends in Cancer 6:7, pages 580-592.
Crossref
Crossref
Loredana Cappellacci, Diego R. Perinelli, Filippo Maggi, Mario Grifantini & Riccardo Petrelli. (2020) Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. Current Medicinal Chemistry 27:15, pages 2449-2493.
Crossref
Crossref
Michael R. Stallcup & Coralie Poulard. (2020) Gene-Specific Actions of Transcriptional Coregulators Facilitate Physiological Plasticity: Evidence for a Physiological Coregulator Code. Trends in Biochemical Sciences 45:6, pages 497-510.
Crossref
Crossref
Li Xu, Juan Feng, Hailong Tang, Ying Dong, Mimi Shu & Xiequn Chen. (2020) Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib. Cell Death & Disease 11:4.
Crossref
Crossref
Ting-Zhi Liu, Yi-Jia Zheng, Zhan-Wen Zhang, Shan-Shan Li, Jiao-Ting Chen, Ai-Hua Peng & Ren-Wei Huang. (2020) Chidamide based combination regimen for treatment of monomorphic epitheliotropic intestinal T cell lymphoma following radical operation: Two case reports. World Journal of Clinical Cases 8:7, pages 1278-1286.
Crossref
Crossref
Zohaib Rana, Sarah Diermeier, Muhammad Hanif & Rhonda J. Rosengren. (2020) Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer. Biomedicines 8:2, pages 22.
Crossref
Crossref
Ying Wu, Lei Wang, Yahui Huang, Shuqiang Chen, Shanchao Wu, Guoqiang Dong & Chunquan Sheng. (2019) Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide. ACS Medicinal Chemistry Letters 11:1, pages 40-44.
Crossref
Crossref
Xu-Wen Guan, Hua-Qing Wang, Wei-Wei Ban, Zhi Chang, Hai-Zhu Chen, Li Jia & Feng-Ting Liu. (2020) Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. Cell Death & Disease 11:1.
Crossref
Crossref
Zuofei Chi, Hongyu Gao, Hui Liu, Bin Wu, Bin Zhang, Min Gu & Wei Yang. (2019) Chidamide induces necroptosis via regulation of c‑FLIPL expression in Jurkat and HUT‑78 cells. Molecular Medicine Reports.
Crossref
Crossref
Jie-Huan Zhang, Madhusoodanan Mottamal, Hai-Shan Jin, Shanchun Guo, Yan Gu, Guangdi Wang & Li-Ming Zhao. (2019) Design, synthesis and evaluation of belinostat analogs as histone deacetylase inhibitors. Future Medicinal Chemistry 11:21, pages 2765-2778.
Crossref
Crossref
Shabir Ahmad GanaiShabir Ahmad Ganai. 2019. Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders. Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders
59
63
.
Martin Marek, Tajith B. Shaik, Tino Heimburg, Alokta Chakrabarti, Julien Lancelot, Elizabeth Ramos-Morales, Cyrielle Da Veiga, Dmitrii Kalinin, Jelena Melesina, Dina Robaa, Karin Schmidtkunz, Takayoshi Suzuki, Ralph Holl, Eric Ennifar, Raymond J. Pierce, Manfred Jung, Wolfgang Sippl & Christophe Romier. (2018) Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants. Journal of Medicinal Chemistry 61:22, pages 10000-10016.
Crossref
Crossref
Yufeng Shang, Xiaorui Fu, Yu Chang, Yanan Li & Mingzhi Zhang. (2018) B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma. Scientific Reports 8:1.
Crossref
Crossref
Daohong Chen. (2018) Dual Targeting Autoimmunity and Cancer: From Biology to Medicine. The Journal of Clinical Pharmacology 58:8, pages 990-996.
Crossref
Crossref
Jelena Melesina, Lucas Praetorius, Conrad V Simoben, Dina Robaa & Wolfgang Sippl. (2018) Design of selective histone deacetylase inhibitors: rethinking classical pharmacophore. Future Medicinal Chemistry 10:13, pages 1537-1540.
Crossref
Crossref
Anu Prakash, Juan Garcia-Moreno, James Brown & Emer Bourke. (2018) Clinically Applicable Inhibitors Impacting Genome Stability. Molecules 23:5, pages 1166.
Crossref
Crossref
Jinyu Yang, Gaoliang Cheng, Qihao Xu, Shenglin Luan, Shuxiang Wang, Dan Liu & Linxiang Zhao. (2018) Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif. Bioorganic & Medicinal Chemistry 26:8, pages 1418-1425.
Crossref
Crossref
Qing Zhang, Yifan Dai, Zhiming Cai & Lisha Mou. (2018) HDAC Inhibitors: Novel Immunosuppressants for Allo- and Xeno- Transplantation. ChemistrySelect 3:1, pages 176-187.
Crossref
Crossref
Gerald Davies, Liubov Lobanova, Wojciech Dawicki, Gary Groot, John R. Gordon, Matthew Bowen, Troy Harkness & Terra Arnason. (2017) Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. PLOS ONE 12:12, pages e0187191.
Crossref
Crossref